Aura Biosciences Inc (AURA) Fair Value & Analysis
Healthcare · US · Market cap $797M · ISIN US05153U1079
What is Aura Biosciences Inc really worth?
Aura Biosciences Inc
AURA · US
Below-average quality, and trading another 569% above our fair value of $1.13.
As of Aug 16, 2026, the fair value of Aura Biosciences Inc is $1.13 per share against a price of $7.56, so the fair value sits 85% below the price. A model estimate blended from multiple valuation models, recalculated regularly.
Risks
Fair value as of: Aug 16, 2026
From 1 valuation models · updated 21 days ago
Share price +5.3% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case ($1.41). The favourable scenario is already priced in.
- Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range ($0.7500 to $1.41) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 16, 2026.
How to read this chart
58‑month range $4.90 – $24.89 · fair‑value band $0.7500 – $1.41 · the $7.56 price screens above the $1.13 fair value. Dashed = 300-day average. As of Aug 16, 2026.
Analysis
Aura Biosciences Inc (AURA) currently trades at $7.56, while our model-based Fair Value estimate is $1.13, implying the stock looks roughly 568.9% overvalued today. The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
It earns a return on equity of −95.6%. The balance sheet holds a net cash position of $42.1M. Fundamentals as of Aug 16, 2026
Our scenario range runs from $0.7500 (bear case) to $1.41 (bull case); at $7.56, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 21% below its 52-week high and 60% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −56% fair-value upside, at −85%, AURA screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 1 models by family
Notify me when AURA reaches fair value
Put AURA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 39 · Market factors (momentum, volatility) 61
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Full company description
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Aura Biosciences Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$106M in FY2025.
AURA screens 569% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 627 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $547.55 | $278.78 | −49% |
| Regeneron Pharmaceuticals, Inc REGN | $807.71 | $594.40 | −26% |
| argenx SE ARGX | €877.60 | €292.84 | −67% |
| BeOne Medicines AG 688235 | ¥271.00 | ¥47.36 | −83% |
| Samsung Biologics Co 207940 | 1,518,000 KRW | 1,055,793 KRW | −30% |
| Alnylam Pharmaceuticals, Inc ALNY | $228.61 | $51.70 | −77% |
| Royalty Pharma plc RPRX | $60.58 | $24.22 | −60% |
| Celltrion, Inc 068270 | 190,700 KRW | 74,519 KRW | −61% |
| BioNTech SE BNTX | $103.76 | $45.70 | −56% |
| Incyte Corporation INCY | $123.22 | $115.79 | −6% |
Compare Aura Biosciences Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Aura Biosciences Inc (AURA) overvalued or undervalued?
What is the fair value of AURA?
What is the quality score of AURA?
What is the price target for Aura Biosciences Inc (AURA)?
What is the Aura Biosciences Inc stock forecast for 2026?
What is the net profit margin of AURA?
Watch Aura Biosciences Inc in the live analysis
One click puts Aura Biosciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.